Onclive Team

Articles

Median Cost of New Oncology Agents to Exceed $200,000 by 2023

February 26th 2019

The annual cost of new oncology drugs will continue to trend upward over the next 5 years, eventually breaching the $200,000 level.

ACCC Meeting and Summit Prepares Stakeholders for Transformations in Cancer Care

February 25th 2019

The Association of Community Cancer Center's 45th Annual Meeting and Cancer Center Business Summit prepares oncology stakeholders for dramatic transformations in cancer care delivery.

Iomab-B Shows Promise as Novel Conditioning for HSCT in AML

February 25th 2019

More than 90% of older patients with relapsed/refractory acute myeloid leukemia had successful engraftment of allogeneic hematopoietic stem cell transplant preceded by novel conditioning with an iodinated CD45-targeted antibody.

CD30 CAR T Cells Active in Hodgkin Lymphoma

February 25th 2019

Chimeric antigen receptor T cells targeting CD30 proved to be safe and active in relapsed/refractory Hodgkin lymphoma.

Herpes Zoster Vaccine Elicits Robust Immune Response in HSCT Patients

February 25th 2019

Two doses of adjuvanted recombinant zoster vaccine following autologous hematopoietic stem cell transplant led to rapid and durable cell-mediated immune responses, results from a subgroup analysis of a large randomized, placebo-controlled trial showed.1

Thrombotic Microangiopathy a Threat After Hematopoietic Cell Transplant

February 23rd 2019

Transplant-associated thrombotic microangiopathy occurred in as many as 36% of hematopoietic cell transplants and significantly increased the risk of transplant-related mortality.

Ibrutinib Plus CAR T-Cell Therapy Boosts Response in CLL

February 22nd 2019

Patients with relapsed/refractory chronic lymphocytic leukemia had an improved response rate with chimeric antigen receptor T-cell therapy if they also received ibrutinib.

City of Hope Awarded Lymphoma SPORE Grant From NCI

February 22nd 2019

An international leader in finding new, innovative treatments for lymphoma patients, City of Hope announced today that it has received its third lymphoma Specialized Programs of Research Excellence grant from the National Cancer Institute.

Pretransplant MRD Prognostic for Outcomes in Adults With ALL

February 22nd 2019

Adults with acute lymphoblastic leukemia had worse outcomes, including lower survival, after myeloablative allogeneic transplantation if they remained positive for minimal residual disease at the time of transplant.

Research Finds Rivaroxaban Significantly Reduces Blood Clots in Patients With Cancer

February 21st 2019

Cleveland Clinic research has found that the blood thinner rivaroxaban significantly reduces venous thromboembolism (VTE)—a blood clot in the venous system—and VTE-related death for outpatient, high-risk cancer patients while they are taking the oral anticoagulant.

Getting Up to Speed with Progress Made in GU Cancers in Memphis

February 20th 2019

We traveled to Memphis, Tennessee for a State of the Science Summit™ on Genitourinary Cancers, which focused on advances made in the treatment landscapes of metastatic renal cell carcinoma and prostate cancer.

NCCN Guidelines Reflect Recent FDA Approvals for Hematologic Malignancies

February 13th 2019

New options for patients with hematologic malignancies stemming from recent FDA approvals are making an impact on treatment strategies recommended in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology.

Highlighting Headway Made in NSCLC in New York

February 13th 2019

We traveled to New York, New York, for a State of the Science Summit™ on Advanced Non–Small Cell Lung Cancer, which focused on topics ranging from surgical techniques, to headway made in immunotherapy, to emerging biomarkers, to diagnostic advancements.

Examining Breakthroughs Made in Breast Cancer in Minneapolis

February 7th 2019

We traveled to Minneapolis, Minnesota, for a State of the Science Summit on Breast Cancer, which focused on surgical approaches for node-positive breast cancer, the use of CDK4/6 inhibitors in hormone receptor–positive disease, and emerging drug therapies in triple-negative disease.

Roswell Park Researchers Propose 2 New Strategies for Treating Pancreatic Cancer

February 1st 2019

In a pair of new studies, researchers from Roswell Park Comprehensive Cancer Center outline strategies for overcoming pancreatic cancer’s resistance to treatment through approaches that exploit this cancer’s reliance on uncontrolled, or deregulated, cell proliferation.

JTCC Leading Enrollment for WIZARD Study Evaluating DSP-7888 in Recurrent Glioblastoma

February 1st 2019

John Theurer Cancer Center at Hackensack Meridian Health Hackensack University Medical Center announced that it is leading enrollment worldwide for WIZARD 201G, a global Phase 2 study in glioblastoma.

Navigating New Advances Made in NSCLC in New York

January 31st 2019

We traveled to Syracuse, New York, for a State of the Science Summit on Advanced Non–Small Cell Lung Cancer, which focused on practice-change clinical trials in the space, as well as novel approaches to treatment with checkpoint inhibitors, targeted therapies, radiation, and minimally invasive surgery.

Roswell Park Becomes Region's Only NPF Center for Pancreatic Cancer

January 30th 2019

The National Pancreas Foundation (NPF) has designated Roswell Park Comprehensive Cancer Center as an NPF Center for pancreatic cancer.

Dana-Farber Researchers Win Grand Challenge Funding from Cancer Research UK

January 25th 2019

Dana-Farber Cancer Institute researchers are Grand Challenge winners for a project that aims to discover how certain microbes inside the body lead to colorectal cancer and influence a patient’s response to treatment.

Making Moves in Multiple Myeloma in NYC

January 24th 2019

We traveled to New York City, New York, for a State of the Science Summit on Multiple Myeloma, which focused on stem cell transplant, minimal residual disease, maintenance options, and treatment approaches for newly diagnosed myeloma.